Abstract
Currently, digital healthcare technologies based on Internet of Things (IOT) are emerging, and the market for digital healthcare was estimated to be 151.5 billion dollars by 2020. Among the digital healthcare technologies, disease diagnosis is attracting maximum attention. Traditional diagnostic methods, such as radiology and human biological material analysis, have limitations of long study time, high cost, radiation exposure, and pain. Therefore, non-invasive diagnostics methods, for early diagnosis of specific diseases and personal healthcare management, have attracted attention.Breath sensors are one of the promising candidates for the realization of non-invasive diagnosis owing to their ease of use, safety, and cost effectiveness. The exhaled breath analysis technique holds great promise as a non-invasive method for diagnosing lung cancer. In the breath of lung cancer patients, various volatile organic compounds (VOCs) markers are generated during metabolic processes. Analyzing these VOCs markers presents a compelling avenue for early and non-invasive lung cancer diagnosis. Solid state gas sensors capable of measuring specific VOCs are currently being researched and utilized as commercial gas sensors for this purpose. However, the concentration of lung cancer VOCs markers in exhaled breath is commonly very low, and individual commercial gas sensors often lack the necessary sensitivity and selectivity to accurately diagnose lung cancer. In this study, we propose a multimodal solid state electronic biosensor system designed to differentiate lung cancer VOCs characteristics among multiple VOCs, enabling exhalation-based lung cancer diagnosis. Initially, we developed multimodal biosensors using more than 20 gas sensors, consisting of metal oxide semiconductor sensors, electrochemical sensors, photoionized detectors, metalorganic frame sensors and so on. And each exhibiting varying sensitivity profiles for complex gas mixtures. Additionally, we designed a classification algorithm based on convolutional neural networks (CNN) and multi-layered perceptron (MLP) to distinguish between lung cancer patients and healthy individuals using the output from these diverse multimodal gas sensors. To evaluate the system's performance, we collected exhaled air samples from 74 lung cancer patients and 107 normal subjects, conducting clinical trials with our developed system. We did model evaluation with confusion matrix and ROC curve. The results of these tests confirmed that our system achieved a high predictive accuracy of over 95% in classifying lung cancer patients. The simplicity of the sensor configuration in our developed system makes it suitable for large-scale screening tests to identify potential candidates for precise lung cancer diagnosis. This technology has the potential to contribute to reduced national welfare costs and improved patient survival rates through early diagnosis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.